Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × JNJ-64264681 × Myeloid × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡